The cost-effectiveness of guideline-driven use of drug-eluting stents: propensity-score matched analysis of a seven-year multicentre experience

References

• Babapulle MN, Joseph L, Belisle P, et al. A hierarchical Bayesian meta- analysis of randomised clinical trials of drug-eluting stents. Lancet. 2004;364:583–591.
   PubMed Web of Science ®Google Scholar
• Piccolo R, Bonaa KH, Efthimiou O, et al. Drug-eluting or bare-metal stents for percutaneous coronary intervention: a systematic review and individual patient data meta-analysis of randomised clinical trials. Lancet. 2019;393(10190):2503–2510.
   PubMed Web of Science ®Google Scholar
• Ong AT, McFadden EP, Regar E, et al. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol. 2005;45:2088–2092.
   PubMed Web of Science ®Google Scholar
• de la Torre Hernández JM, Windecker S. Very late stent thrombosis with newer drug-eluting stents: no longer an issue? Rev Esp Cardiol (Engl Ed). 2012;65(7):595–598.
   PubMed Web of Science ®Google Scholar
• Windecker S, Kolh P, Alfonso F, et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014; 35(37):2541–2619.
   PubMed Web of Science ®Google Scholar
• Sabate M, Raber L, Heg D, et al. Comparison of newer-generation drug-eluting with bare-metal stents in patients with acute ST-segment elevation myocardial infarction: a pooled analysis of the EXAMINATION (clinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTION) and COMFORTABLE-AMI (Comparison of Biolimus Eluted From an Erodible Stent Coating With Bare Metal Stents in Acute ST-Elevation Myocardial Infarction) trials. JACC Cardiovasc Interv. 2014;7(1):55–63.
   PubMed Web of Science ®Google Scholar
• Yan BP, Ajani AE, Duffy SJ, et al. Use of drug-eluting stents in Victorian public hospitals. Med J Austr. 2006;185:363–367.
   PubMed Web of Science ®Google Scholar
• Cooper LM, Linde-Zwirble W. Cost-effectiveness of drug-eluting stents: real-world scrutiny of the BASKET trial of real-world usage. Exp Opin Drug Deliv. 2006;3:305–309.
   PubMed Web of Science ®Google Scholar
• Ligthart S, Vlemmix F, Dendukuri N, et al. The cost-effectiveness of drug-eluting stents: a systematic review. CMAJ. 2007;176:199–205.
   PubMed Web of Science ®Google Scholar
• Neyt M, Van BH, Devriese S, et al. Cost-effectiveness analyses of drug eluting stents versus bare metal stents: a systematic review of the literature. Heal Pol. 2009;91:107–120.
   Google Scholar
• Carrillo D, Ortiz Sierra M, Cepeda Gil M, et al. Cost-effectiveness of drug eluting stents versus bare metal stents in coronary heart. Argentine J Cardiol. 2012. [cited 2015 Jan 27]. Available from: http://ppct.caicyt.gov.ar/index.php/rac/article/view/1024.
   Google Scholar
• Ajani AE, Szto G, Duffy SJ, et al. The foundation and launch of the Melbourne Interventional Group: a collaborative interventional cardiology project. Heart Lung Circ. 2006;15:44–47.
   PubMedGoogle Scholar
• Chan W, Clark DJ, Ajani AE, et al. Progress towards a National Cardiac Procedure Database-development of the Australasian Society of Cardiac and Thoracic Surgeons (ASCTS) and Melbourne Interventional Group (MIG) registries. Heart Lung Circ. 2011;20:10–18.
   PubMed Web of Science ®Google Scholar
• Baumler M, Stargardt T, Schreyogg J, et al. Cost effectiveness of drug-eluting stents in acute myocardial infarction patients in Germany: results from administrative data using a propensity score-matching approach. Appl Heal Econ Heal Pol. 2012;10:235–248.
   PubMedGoogle Scholar
• Goeree R, Bowen JM, Blackhouse G, et al. Economic evaluation of drug-eluting stents compared to bare metal stents using a large prospective study in Ontario. Int J Technol Assess Heal Care. 2009;25:196–207.
   PubMed Web of Science ®Google Scholar
• Austin PC, Mamdani MM. A comparison of propensity score methods: a case-study estimating the effectiveness of post-AMI statin use. Stat Med. 2006;25:2084–2106.
   PubMed Web of Science ®Google Scholar
• Ajani AE, Reid CM, Duffy SJ, et al. Outcomes after percutaneous coronary intervention in contemporary Australian practice: insights from a large multicentre registry. Med J Austr. 2008;189:423–428.
   PubMed Web of Science ®Google Scholar
• Cole JA, Brennan AL, Ajani AE, et al. Cardiovascular medication use following percutaneous coronary intervention: the Australian experience. Cardiovasc Ther. 2014;32:47–51.
   PubMed Web of Science ®Google Scholar
• Australian Institute of Health and Welfare. 2016. Health expenditure Australia 2014–15. Health and welfare expenditure series no. 57. Cat. no. HWE 67. Canberra: AIHW.
   Google Scholar
• Australian Government [Internet]. Australian Refined Diagnostic Related Groups (AR-DRG). 2011. [cited 2012 Nov 1]. Available from: http://www.health.gov.au/internet/main/publishing.nsf/content/health-casemix-ardrg1.htm.
   Google Scholar
• Australian Government [Internet]. Pharmaceutical Benefits Scheme (PBS): medicine listing. 2012. [cited 2013 Feb 24]. Available from: http://www.pbs.gov.au/browse/medicine-listing.
   Google Scholar
• Ariyaratne TV, Ademi Z, Duffy SJ, et al. Cardiovascular readmissions and excess costs following percutaneous coronary intervention in patients with chronic kidney disease: data from a large multi-centre Australian registry. Int J Cardiol. 2013;168:2783–2790
   PubMedGoogle Scholar
• Grines CL. Off-label use of drug-eluting stents putting it in perspective. J Am Coll Cardiol. 2008;51:615–617.
   PubMed Web of Science ®Google Scholar
• Stefanini GG, Meier B. An update on drug-eluting stents versus bare-metal stents in PCI treatment: are there any remaining indications for BMS use? Interv Cardiol. 2015;7:497–505.
   Google Scholar
• Morice M-C, Urban P, Greene S, et al. Why are we still using coronary bare- metal stents? J Am Coll Cardiol. 2013;61:1122–1123.
   PubMed Web of Science ®Google Scholar
• Bagust A, Grayson AD, Palmer ND, et al. Cost effectiveness of drug eluting coronary artery stenting in a UK setting: cost-utility study. Heart. 2006;92:68–74.
   PubMed Web of Science ®Google Scholar
• Lord SJ, Howard K, Allen F, et al. A systematic review and economic analysis of drug-eluting coronary stents available in Australia. Med J Austr. 2005;183:464–471.
   PubMed Web of Science ®Google Scholar
• Cutlip DE, Chauhan MS, Baim DS, et al. Clinical restenosis after coronary stenting: perspectives from multicenter clinical trials. J Am Coll Cardiol. 2002;40:2082–2089.
   PubMed Web of Science ®Google Scholar
• Fischman DL, Leon MB, Baim DS, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med. 1994;331:496–501.
   PubMed Web of Science ®Google Scholar
• Holmes DR, Jr, Leon MB, Moses JW, et al. Analysis of 1-year clinical outcomes in the SIRIUS trial: a randomized trial of a sirolimus-eluting stent versus a standard stent in patients at high risk for coronary restenosis. Circulation. 2004;109:634–640.
   PubMed Web of Science ®Google Scholar